Shin-Ichi Araki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shin-Ichi Araki has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Hiroshi Maegawa
Department of Medicine Shiga University of Medical Science Otsu Shiga Japan
17 shared publications Atsunori Kashiwagi
Department of Medicine, Shiga University of Medical Science, Otsu, Japan
13 shared publicationsTakashi Uzu
Department of Medicine, Shiga University of Medical Science, Otsu, Japan
13 shared publicationsDaisuke Koya
Department of Diabetology & Endocrinology, Kanazawa Medical University, Ishikawa, Japan
12 shared publicationsMasakazu Haneda
Department of Medicine, Asahikawa Medical University, Hokkaido, Japan
11 shared publicationsKeiji Isshiki
Department of Medicine, Shiga University of Medical Science, Otsu, Japan
8 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Springer Nature in BMC Nephrology
Efficacy and safety of single high-dose intravenous ferric carboxymaltose in patients undergoing hemodialysis: a multicenter, single-arm, open-label, clinical trial
Background: Iron-deficiency anemia is common in patients undergoing hemodialysis, and intravenous iron therapy is often preferred because oral iron is poorly tolerated and less effective. Ferric caboxymaltose, a high-dose intravenous iron formulation, has recently become available in Japan. However, evidence regarding its efficacy and safety in hemodialysis patients remains limited. Therefore, this study investigated the efficacy and safety of a single intravenous administration of ferric carboxymaltose containing 500 mg of iron in Japanese patients undergoing hemodialysis. Methods: A 12-week, multicenter, prospective, open-label, single-arm trial was conducted, enrolling 30 Japanese patients undergoing hemodialysis with hemoglobin < 10 g/dL and iron-deficiency (serum ferritin < 100 ng/mL or transferrin saturation [TSAT] < 20%). Hemoglobin, iron-related parameters (serum ferritin, TSAT, 8-hydroxydeoxyguanosine [8-OHdG], hepcidin, intact fibroblast growth factor 23 [FGF-23], and phosphate), and quality of life (Short Form-36 Health Survey [SF-36] and EuroQol 5-Dimension 5-Level) were assessed at baseline and at weeks 1, 2, 4, 8, and 12. The primary endpoint was the change in hemoglobin level from baseline to week 4, assessed using a one-sample t-test against a threshold of 0.5 g/dL. Secondary outcomes included longitudinal changes in hemoglobin, iron-related parameters, and quality of life from baseline to each post-treatment time point, analyzed using a linear mixed-effects model. The occurrence of adverse events was observed over 12 weeks. Results: The mean hemoglobin levels significantly increased by + 0.50 g/dL (95% confidence interval: 0.18–0.82, P = 0.003) from baseline to week 4, and the increase was maintained through week 12. All iron-related parameters peaked by week 2 and subsequently declined; however, serum ferritin levels remained significantly elevated at week 12. SF-36 vitality, general health and mental health scores increased significantly at 4 weeks compared with baseline. No serious adverse events were observed, although one case of arteriovenous fistula occlusion occurred. Conclusions: Single intravenous iron therapy with ferric carboxymaltose containing 500 mg of iron effectively increased hemoglobin levels without serious adverse events. Further long-term clinical trials are warranted to confirm the efficacy and safety of periodic ferric carboxymaltose therapy in patients undergoing hemodialysis. Trial registration: This study was prospectively registered with the Japan Registry of Clinical Trials on 23 May, 2023 (registration number jRCTs051230025).
- 29 June 2026
- Published by Springer Nature in BMC Nephrology
Open AccessEfficacy and safety of single high-dose intravenous ferric carboxymaltose in patients undergoing hemodialysis: a multicenter, single-arm, open-label, clinical trial
Background: Iron-deficiency anemia is common in patients undergoing hemodialysis, and intravenous iron therapy is often preferred because oral iron is poorly tolerated and less effective. Ferric caboxymaltose, a high-dose intravenous iron formulation, has recently become available in Japan. However, evidence regarding its efficacy and safety in hemodialysis patients remains limited. Therefore, this study investigated the efficacy and safety of a single intravenous administration of ferric carboxymaltose containing 500 mg of iron in Japanese patients undergoing hemodialysis. Methods: A 12-week, multicenter, prospective, open-label, single-arm trial was conducted, enrolling 30 Japanese patients undergoing hemodialysis with hemoglobin < 10 g/dL and iron-deficiency (serum ferritin < 100 ng/mL or transferrin saturation [TSAT] < 20%). Hemoglobin, iron-related parameters (serum ferritin, TSAT, 8-hydroxydeoxyguanosine [8-OHdG], hepcidin, intact fibroblast growth factor 23 [FGF-23], and phosphate), and quality of life (Short Form-36 Health Survey [SF-36] and EuroQol 5-Dimension 5-Level) were assessed at baseline and at weeks 1, 2, 4, 8, and 12. The primary endpoint was the change in hemoglobin level from baseline to week 4, assessed using a one-sample t-test against a threshold of 0.5 g/dL. Secondary outcomes included longitudinal changes in hemoglobin, iron-related parameters, and quality of life from baseline to each post-treatment time point, analyzed using a linear mixed-effects model. The occurrence of adverse events was observed over 12 weeks. Results: The mean hemoglobin levels significantly increased by + 0.50 g/dL (95% confidence interval: 0.18–0.82, P = 0.003) from baseline to week 4, and the increase was maintained through week 12. All iron-related parameters peaked by week 2 and subsequently declined; however, serum ferritin levels remained significantly elevated at week 12. SF-36 vitality, general health and mental health scores increased significantly at 4 weeks compared with baseline. No serious adverse events were observed, although one case of arteriovenous fistula occlusion occurred. Conclusions: Single intravenous iron therapy with ferric carboxymaltose containing 500 mg of iron effectively increased hemoglobin levels without serious adverse events. Further long-term clinical trials are warranted to confirm the efficacy and safety of periodic ferric carboxymaltose therapy in patients undergoing hemodialysis. Trial registration: This study was prospectively registered with the Japan Registry of Clinical Trials on 23 May, 2023 (registration number jRCTs051230025).
- 16 March 2026
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 40 (5) , 109309
Prediction of worsening of renal function by the combination of an initial decline in renal function and blood pressure-lowering effect after renin–angiotensin system blockade in patients with type 2 diabetes mellitus (JDDM 83)
- 16 March 2026
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 40 (5) , 109309
Prediction of worsening of renal function by the combination of an initial decline in renal function and blood pressure-lowering effect after renin–angiotensin system blockade in patients with type 2 diabetes mellitus (JDDM 83)
- 16 November 2024
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 29 (4) , 452-459
SGLT2 inhibitors increase low serum magnesium levels in patients with chronic kidney disease immediately after treatment
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown in clinical trials to increase serum Mg2+ levels in patients with type 2 diabetes mellitus. However, it is unclear whether this effect is similarly observed in patients with chronic kidney disease (CKD) and whether such an increase is observed immediately after treatment. Methods Our retrospective observational study included the 62 patients with CKD who started SGLT2 inhibitor therapy at our institution between 2017 and 2022 and who had complete data on serum Mg2+ measurements at baseline and at 1, 3, and 6 months after treatment. Patients were divided into three subgroups, stratified by serum Mg2+ levels at baseline. We evaluated the changes in serum Mg2+ levels from baseline to 6 months after treatment and the factors associated with these changes. Results Median eGFR and mean serum Mg2+ at baseline were 33.5 mL/min/1.73 m2 and 2.03 mg/dL, respectively. Treatment with SGLT2 inhibitors significantly increased serum Mg2+ levels immediately from 1 month after treatment compared with those at baseline and persisted over 6 months, with an overall mean change of 0.13 mg/dL from baseline to 6 months. This increased effect was observed in the low and middle tertile subgroups, but not in the high tertile subgroup. Multivariate linear regression analysis revealed that baseline serum Mg2+ levels and sodium-chloride differences, as a parameter of acid–base status, were independently associated with these changes. Conclusions SGLT2 inhibitors increased serum Mg2+ levels in patients with CKD, particularly those with lower baseline Mg2+ levels, potentially improving their prognosis.
- 16 November 2024
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 29 (4) , 452-459
SGLT2 inhibitors increase low serum magnesium levels in patients with chronic kidney disease immediately after treatment
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown in clinical trials to increase serum Mg2+ levels in patients with type 2 diabetes mellitus. However, it is unclear whether this effect is similarly observed in patients with chronic kidney disease (CKD) and whether such an increase is observed immediately after treatment. Methods Our retrospective observational study included the 62 patients with CKD who started SGLT2 inhibitor therapy at our institution between 2017 and 2022 and who had complete data on serum Mg2+ measurements at baseline and at 1, 3, and 6 months after treatment. Patients were divided into three subgroups, stratified by serum Mg2+ levels at baseline. We evaluated the changes in serum Mg2+ levels from baseline to 6 months after treatment and the factors associated with these changes. Results Median eGFR and mean serum Mg2+ at baseline were 33.5 mL/min/1.73 m2 and 2.03 mg/dL, respectively. Treatment with SGLT2 inhibitors significantly increased serum Mg2+ levels immediately from 1 month after treatment compared with those at baseline and persisted over 6 months, with an overall mean change of 0.13 mg/dL from baseline to 6 months. This increased effect was observed in the low and middle tertile subgroups, but not in the high tertile subgroup. Multivariate linear regression analysis revealed that baseline serum Mg2+ levels and sodium-chloride differences, as a parameter of acid–base status, were independently associated with these changes. Conclusions SGLT2 inhibitors increased serum Mg2+ levels in patients with CKD, particularly those with lower baseline Mg2+ levels, potentially improving their prognosis.
- Open Access
The Role of CD38 in the Pathogenesis of Cardiorenal Metabolic Disease and Aging, an Approach from Basic Research
Aging is a major risk factor for the leading causes of mortality, and the incidence of age-related diseases including cardiovascular disease, kidney disease and metabolic disease increases with age. NAD+ is a classic coenzyme that exists in all species, and that plays a crucial role in oxidation–reduction reactions. It is also involved in the regulation of many cellular functions including inflammation, oxidative stress and differentiation. NAD+ declines with aging in various organs, and the reduction in NAD+ is possibly involved in the development of age-related cellular dysfunction in cardiorenal metabolic organs through the accumulation of inflammation and oxidative stress. Levels of NAD+ are regulated by the balance between its synthesis and degradation. CD38 is the main NAD+-degrading enzyme, and CD38 is activated in response to inflammation with aging, which is associated with the reduction in NAD+ levels. In this review, focusing on CD38, we discuss the role of CD38 in aging and the pathogenesis of age-related diseases, including cardiorenal metabolic disease.
Open AccessThe Role of CD38 in the Pathogenesis of Cardiorenal Metabolic Disease and Aging, an Approach from Basic Research
Aging is a major risk factor for the leading causes of mortality, and the incidence of age-related diseases including cardiovascular disease, kidney disease and metabolic disease increases with age. NAD+ is a classic coenzyme that exists in all species, and that plays a crucial role in oxidation–reduction reactions. It is also involved in the regulation of many cellular functions including inflammation, oxidative stress and differentiation. NAD+ declines with aging in various organs, and the reduction in NAD+ is possibly involved in the development of age-related cellular dysfunction in cardiorenal metabolic organs through the accumulation of inflammation and oxidative stress. Levels of NAD+ are regulated by the balance between its synthesis and degradation. CD38 is the main NAD+-degrading enzyme, and CD38 is activated in response to inflammation with aging, which is associated with the reduction in NAD+ levels. In this review, focusing on CD38, we discuss the role of CD38 in aging and the pathogenesis of age-related diseases, including cardiorenal metabolic disease.
- 21 February 2022
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1868 (5) , 166368
Inhibition of mitochondrial fission protects podocytes from albumin-induced cell damage in diabetic kidney disease
- 21 February 2022
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1868 (5) , 166368
Inhibition of mitochondrial fission protects podocytes from albumin-induced cell damage in diabetic kidney disease
- Open Access
- 19 February 2021
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 30 (8) , 716-726
Genome-wide association studies identify two novel loci conferring susceptibility to diabetic retinopathy in Japanese patients with type 2 diabetes
Several reports have suggested that genetic susceptibility contributes to the development and progression of diabetic retinopathy. We aimed to identify genetic loci that confer susceptibility to diabetic retinopathy in Japanese patients with type 2 diabetes. We analysed 5 790 508 single nucleotide polymorphisms (SNPs) in 8880 Japanese patients with type 2 diabetes, 4839 retinopathy cases and 4041 controls, as well as 2217 independent Japanese patients with type 2 diabetes, 693 retinopathy cases and 1524 controls. The results of these two genome-wide association studies (GWAS) were combined with an inverse variance meta-analysis (Stage-1), followed by de novo genotyping for the candidate SNP loci (P < 1.0 × 10−4) in an independent case–control study (Stage-2, 2260 cases and 723 controls). After combining the association data (Stages 1 and 2) using meta-analysis, the associations of two loci reached a genome-wide significance level: rs12630354 near STT3B on chromosome 3, P = 1.62 × 10−9, odds ratio (OR) = 1.17, 95% confidence interval (CI) 1.11–1.23, and rs140508424 within PALM2 on chromosome 9, P = 4.19 × 10−8, OR = 1.61, 95% CI 1.36–1.91. However, the association of these two loci was not replicated in Korean, European or African American populations. Gene-based analysis using Stage-1 GWAS data identified a gene-level association of EHD3 with susceptibility to diabetic retinopathy (P = 2.17 × 10−6). In conclusion, we identified two novel SNP loci, STT3B and PALM2, and a novel gene, EHD3, that confers susceptibility to diabetic retinopathy; however, further replication studies are required to validate these associations.
- 19 February 2021
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 30 (8) , 716-726
Open AccessGenome-wide association studies identify two novel loci conferring susceptibility to diabetic retinopathy in Japanese patients with type 2 diabetes
Several reports have suggested that genetic susceptibility contributes to the development and progression of diabetic retinopathy. We aimed to identify genetic loci that confer susceptibility to diabetic retinopathy in Japanese patients with type 2 diabetes. We analysed 5 790 508 single nucleotide polymorphisms (SNPs) in 8880 Japanese patients with type 2 diabetes, 4839 retinopathy cases and 4041 controls, as well as 2217 independent Japanese patients with type 2 diabetes, 693 retinopathy cases and 1524 controls. The results of these two genome-wide association studies (GWAS) were combined with an inverse variance meta-analysis (Stage-1), followed by de novo genotyping for the candidate SNP loci (P < 1.0 × 10−4) in an independent case–control study (Stage-2, 2260 cases and 723 controls). After combining the association data (Stages 1 and 2) using meta-analysis, the associations of two loci reached a genome-wide significance level: rs12630354 near STT3B on chromosome 3, P = 1.62 × 10−9, odds ratio (OR) = 1.17, 95% confidence interval (CI) 1.11–1.23, and rs140508424 within PALM2 on chromosome 9, P = 4.19 × 10−8, OR = 1.61, 95% CI 1.36–1.91. However, the association of these two loci was not replicated in Korean, European or African American populations. Gene-based analysis using Stage-1 GWAS data identified a gene-level association of EHD3 with susceptibility to diabetic retinopathy (P = 2.17 × 10−6). In conclusion, we identified two novel SNP loci, STT3B and PALM2, and a novel gene, EHD3, that confers susceptibility to diabetic retinopathy; however, further replication studies are required to validate these associations.
- Open Access
- 20 June 2020
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 12 (1) , 6-20
Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients
Recent major clinical trials of the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes have shown that they reduce three‐point major adverse cardiovascular events, cardiovascular death, hospitalization for heart failure (HF) and a composite renal outcome. These beneficial effects of SGLT2 inhibitors are also evident in type 2 diabetes patients with a previous history of atherosclerotic cardiovascular disease or advanced renal disease. HF is a major determinant of the prognosis of diabetes patients. Although HF with low ejection fraction can be effectively treated with antihypertensive drugs, these treatments do not reduce mortality in HF patients with preserved ejection fraction (HFpEF). HFpEF is clinically characterized by left ventricular diastolic dysfunction, perivascular fibrosis and stiffness of cardiomyocytes, defined as “cardiomyopathy”. Therefore, HFpEF is considered to be an entirely separate entity to HF with low ejection fraction. Recent studies have suggested that HFpEF might be treatable using SGLT2 inhibitors, which ameliorate visceral adiposity, insulin resistance, hyperglycemia, hyperlipidemia, volume overload, hypertension and cardiac inflammation. In the final part of the present review, we discuss the biochemical and molecular mechanisms of the effects of SGLT2 inhibitors in type 2 diabetes patients with HFpEF. These involve amelioration of the low nitric oxide production and oxidative stress, a reduction in cardiac inflammatory cytokine signaling, inhibition of Ca2+ overload, and an improvement in cardiac energy metabolism as a result of ketone body production. Investigations of the beneficial effects of SGLT2 inhibitors on cardiorenal outcomes, including hospitalization for HF, are now being carried out in preclinical and clinical studies.
- 20 June 2020
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 12 (1) , 6-20
Open AccessSodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients
Recent major clinical trials of the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes have shown that they reduce three‐point major adverse cardiovascular events, cardiovascular death, hospitalization for heart failure (HF) and a composite renal outcome. These beneficial effects of SGLT2 inhibitors are also evident in type 2 diabetes patients with a previous history of atherosclerotic cardiovascular disease or advanced renal disease. HF is a major determinant of the prognosis of diabetes patients. Although HF with low ejection fraction can be effectively treated with antihypertensive drugs, these treatments do not reduce mortality in HF patients with preserved ejection fraction (HFpEF). HFpEF is clinically characterized by left ventricular diastolic dysfunction, perivascular fibrosis and stiffness of cardiomyocytes, defined as “cardiomyopathy”. Therefore, HFpEF is considered to be an entirely separate entity to HF with low ejection fraction. Recent studies have suggested that HFpEF might be treatable using SGLT2 inhibitors, which ameliorate visceral adiposity, insulin resistance, hyperglycemia, hyperlipidemia, volume overload, hypertension and cardiac inflammation. In the final part of the present review, we discuss the biochemical and molecular mechanisms of the effects of SGLT2 inhibitors in type 2 diabetes patients with HFpEF. These involve amelioration of the low nitric oxide production and oxidative stress, a reduction in cardiac inflammatory cytokine signaling, inhibition of Ca2+ overload, and an improvement in cardiac energy metabolism as a result of ketone body production. Investigations of the beneficial effects of SGLT2 inhibitors on cardiorenal outcomes, including hospitalization for HF, are now being carried out in preclinical and clinical studies.
- 1 April 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 525 (2) , 319-325
Protective role of podocyte autophagy against glomerular endothelial dysfunction in diabetes
- 1 April 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 525 (2) , 319-325
Protective role of podocyte autophagy against glomerular endothelial dysfunction in diabetes
- Open Access
- 13 September 2019
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 11 (1) , 22-24
Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
- 13 September 2019
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 11 (1) , 22-24
Open AccessCombined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
- Open Access
- 19 November 2018
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 10 (4) , 1032-1040
Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014
Aims/Introduction: Diabetic kidney disease is characterized by increased albuminuria and/or a reduced glomerular filtration rate (GFR). We analyzed secular changes in the prevalence of albuminuria and reduced estimated GFR (eGFR) in Japanese patients with type 2 diabetes, and identified factors associated with these changes.Materials and Methods: Using 1996, 2001, 2006 and 2014 cohort data from the Japanese serial cross‐sectional studies conducted at Shiga University of Medical Science, secular changes in the prevalence of diabetic kidney disease (albuminuria and/or reduced eGFR), patient characteristics and their associations were analyzed.Results: The prevalence of microalbuminuria and macroalbuminuria decreased over time, whereas the prevalence of moderately reduced eGFR (30–60 mL/min/1.73 m2) and severely reduced eGFR (2) increased. Severely reduced eGFR was observed mainly in the patients with macroalbuminuria, regardless of year. Conversely, the prevalence of moderately reduced eGFR increased in the patients without macroalbuminuria. Both macroalbuminuria and moderately reduced eGFR without macroalbuminuria in the 2014 cohort were refractory to the recently recommended intensive therapy. Finally, we showed that obesity accompanied by vascular dysfunction was a risk factor for the development of albuminuria, and that age‐dependent arterial stiffness was associated with reduced eGFR without macroalbuminuria in the 2014 cohort.Conclusions: During the past 20 years in Japan, the prevalence of albuminuria declined, whereas that of reduced eGFR increased. Additionally, obesity‐ and high age‐related vascular damage seems to be associated with macroalbuminuria and reduced eGFR without macroalbuminuria, respectively.
- 19 November 2018
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 10 (4) , 1032-1040
Open AccessSecular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014
Aims/Introduction: Diabetic kidney disease is characterized by increased albuminuria and/or a reduced glomerular filtration rate (GFR). We analyzed secular changes in the prevalence of albuminuria and reduced estimated GFR (eGFR) in Japanese patients with type 2 diabetes, and identified factors associated with these changes.Materials and Methods: Using 1996, 2001, 2006 and 2014 cohort data from the Japanese serial cross‐sectional studies conducted at Shiga University of Medical Science, secular changes in the prevalence of diabetic kidney disease (albuminuria and/or reduced eGFR), patient characteristics and their associations were analyzed.Results: The prevalence of microalbuminuria and macroalbuminuria decreased over time, whereas the prevalence of moderately reduced eGFR (30–60 mL/min/1.73 m2) and severely reduced eGFR (2) increased. Severely reduced eGFR was observed mainly in the patients with macroalbuminuria, regardless of year. Conversely, the prevalence of moderately reduced eGFR increased in the patients without macroalbuminuria. Both macroalbuminuria and moderately reduced eGFR without macroalbuminuria in the 2014 cohort were refractory to the recently recommended intensive therapy. Finally, we showed that obesity accompanied by vascular dysfunction was a risk factor for the development of albuminuria, and that age‐dependent arterial stiffness was associated with reduced eGFR without macroalbuminuria in the 2014 cohort.Conclusions: During the past 20 years in Japan, the prevalence of albuminuria declined, whereas that of reduced eGFR increased. Additionally, obesity‐ and high age‐related vascular damage seems to be associated with macroalbuminuria and reduced eGFR without macroalbuminuria, respectively.